1. Home
  2. ICU vs LEXX Comparison

ICU vs LEXX Comparison

Compare ICU & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SeaStar Medical Holding Corporation

ICU

SeaStar Medical Holding Corporation

HOLD

Current Price

$2.31

Market Cap

15.9M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.73

Market Cap

17.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICU
LEXX
Founded
2018
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
17.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICU
LEXX
Price
$2.31
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
155.6K
1.4M
Earning Date
11-13-2025
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$881,000.00
$522,000.00
Revenue This Year
$691.85
$13.35
Revenue Next Year
$64.17
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
1195.59
5.05
52 Week Low
$2.20
$0.46
52 Week High
$30.70
$2.04

Technical Indicators

Market Signals
Indicator
ICU
LEXX
Relative Strength Index (RSI) 70.78 47.01
Support Level $2.49 $0.68
Resistance Level $2.98 $0.81
Average True Range (ATR) 0.19 0.08
MACD 0.09 0.02
Stochastic Oscillator 80.42 78.06

Price Performance

Historical Comparison
ICU
LEXX

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: